Human Diversity of Killer Cell Immunoglobulin-Like Receptors and Human Leukocyte Antigen Class I Alleles and Ebola Virus Disease Outcomes.
Ebola virus disease
Ebola virus infection
Guinea
Zaire ebolavirus
human leukocyte antigens
human leukocyte antigens class I
killer cell immunoglobulin-like receptor genes
killer cell immunoglobulin-like receptors
natural killer cells
viral zoonoses
viruses
zoonoses
Journal
Emerging infectious diseases
ISSN: 1080-6059
Titre abrégé: Emerg Infect Dis
Pays: United States
ID NLM: 9508155
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
entrez:
22
12
2020
pubmed:
23
12
2020
medline:
22
6
2021
Statut:
ppublish
Résumé
We investigated the genetic profiles of killer cell immunoglobulin-like receptors (KIRs) in Ebola virus-infected patients. We studied the relationship between KIR-human leukocyte antigen (HLA) combinations and the clinical outcomes of patients with Ebola virus disease (EVD). We genotyped KIRs and HLA class I alleles using DNA from uninfected controls, EVD survivors, and persons who died of EVD. The activating 2DS4-003 and inhibitory 2DL5 genes were significantly more common among persons who died of EVD; 2DL2 was more common among survivors. We used logistic regression analysis and Bayesian modeling to identify 2DL2, 2DL5, 2DS4-003, HLA-B-Bw4-Thr, and HLA-B-Bw4-Ile as probably having a significant relationship with disease outcome. Our findings highlight the importance of innate immune response against Ebola virus and show the association between KIRs and the clinical outcome of EVD.
Identifiants
pubmed: 33350932
doi: 10.3201/eid2701.202177
pmc: PMC7774578
doi:
Substances chimiques
HLA Antigens
0
Receptors, KIR
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
76-84Références
Transpl Immunol. 2002 Aug;10(2-3):147-64
pubmed: 12216946
PLoS Negl Trop Dis. 2017 May 30;11(5):e0005645
pubmed: 28558022
Tissue Antigens. 2007 Nov;70(5):415-22
pubmed: 17854430
J Virol. 2004 Oct;78(19):10370-7
pubmed: 15367603
Front Immunol. 2019 May 17;10:989
pubmed: 31156615
Viral Immunol. 2004;17(3):390-400
pubmed: 15357905
Cell Death Differ. 2015 Aug;22(8):1250-9
pubmed: 26024394
J Clin Invest. 2018 May 1;128(5):1903-1912
pubmed: 29461980
Nucleic Acids Res. 2015 Jan;43(Database issue):D784-8
pubmed: 25414323
Immunogenetics. 2010 Dec;62(11-12):767-71
pubmed: 20878400
JCI Insight. 2020 May 21;5(10):
pubmed: 32434986
J Virol. 2019 May 1;93(10):
pubmed: 30814283
Immunol Rev. 2002 Dec;190:40-52
pubmed: 12493005
Immunol Cell Biol. 2011 Feb;89(2):216-24
pubmed: 20567250
JCI Insight. 2019 Jan 10;4(1):
pubmed: 30626757
Front Immunol. 2018 Jan 05;8:1912
pubmed: 29354127
Semin Immunol. 2008 Dec;20(6):343-52
pubmed: 18635379
Trends Immunol. 2007 Oct;28(10):437-41
pubmed: 17825623
J Exp Med. 2004 Jul 19;200(2):169-79
pubmed: 15249592
Sci Immunol. 2018 Nov 9;3(29):
pubmed: 30413420
Hum Immunol. 2002 Apr;63(4):271-80
pubmed: 12039408
PLoS Negl Trop Dis. 2010 Oct 05;4(10):
pubmed: 20957152
J Autoimmun. 2014 Dec;55:1-9
pubmed: 25260583
Immunotherapy. 2011 Sep;3(9):1075-86
pubmed: 21913830
Int J Immunogenet. 2010 Jun;37(3):159-68
pubmed: 20193031
Bioinformatics. 2005 May 15;21(10):2394-402
pubmed: 15713736
Nat Rev Immunol. 2005 Mar;5(3):201-14
pubmed: 15719024
J Virol. 2019 Apr 17;93(9):
pubmed: 30185599
Am J Pathol. 2003 Dec;163(6):2347-70
pubmed: 14633608
Nat Microbiol. 2018 Oct;3(10):1084-1089
pubmed: 30150734